Cargando…

KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

BACKGROUND: This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. METHODS: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mudduwa, Lakmini, Peiris, Harshini, Gunasekara, Shania, Abeysiriwardhana, Deepthika, Liyanage, Nimsha, Rayala, Suresh K., Liyanage, Thusharie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968668/
https://www.ncbi.nlm.nih.gov/pubmed/29793439
http://dx.doi.org/10.1186/s12885-018-4491-6
_version_ 1783325816128536576
author Mudduwa, Lakmini
Peiris, Harshini
Gunasekara, Shania
Abeysiriwardhana, Deepthika
Liyanage, Nimsha
Rayala, Suresh K.
Liyanage, Thusharie
author_facet Mudduwa, Lakmini
Peiris, Harshini
Gunasekara, Shania
Abeysiriwardhana, Deepthika
Liyanage, Nimsha
Rayala, Suresh K.
Liyanage, Thusharie
author_sort Mudduwa, Lakmini
collection PubMed
description BACKGROUND: This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. METHODS: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features. RESULTS: A total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model. CONCLUSION: Overall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy.
format Online
Article
Text
id pubmed-5968668
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59686682018-05-30 KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy Mudduwa, Lakmini Peiris, Harshini Gunasekara, Shania Abeysiriwardhana, Deepthika Liyanage, Nimsha Rayala, Suresh K. Liyanage, Thusharie BMC Cancer Research Article BACKGROUND: This study was carried out to evaluate the prognostic value of KIBRA in breast cancer. METHODS: This retrospective study included breast cancer patients who sought the services of the immunohistochemistry laboratory of our unit from 2006 to 2015. Tissue microarrays were constructed and immunohistochemical staining was done to assess the KIBRA expression. The Kaplan-Meier model for univariate and Cox-regression model with backward stepwise factor retention method for multivariate analyses were used. Chi square test was used to find out the associations with the established prognostic features. RESULTS: A total of 1124 patients were included in the study and KIBRA staining of 909 breast cancers were available for analysis. Cytoplasmic KIBRA expression was seen in 39.5% and nuclear expression in 44.8%. Overall KIBRA–low breast cancers accounted for 41.5%. KIBRA nuclear expression was significantly associated with positive ER and PR expression. Luminal breast cancer patients who had endocrine therapy and KIBRA-low expression had a RFS disadvantage over those who were positive for KIBRA (p = 0.02). Similarly, patients who received chemotherapy and had overall KIBRA-low expression also demonstrated a RFS disadvantage compared to those who had overall positive KIBRA expression (p = 0.018). This effect of KIBRA was independent of the other factors considered for the model. CONCLUSION: Overall low-KIBRA expression has an independent effect on the RFS and predicts the RFS outcome of luminal breast cancer patients who received endocrine therapy and breast cancer patients who received chemotherapy. BioMed Central 2018-05-24 /pmc/articles/PMC5968668/ /pubmed/29793439 http://dx.doi.org/10.1186/s12885-018-4491-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mudduwa, Lakmini
Peiris, Harshini
Gunasekara, Shania
Abeysiriwardhana, Deepthika
Liyanage, Nimsha
Rayala, Suresh K.
Liyanage, Thusharie
KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
title KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
title_full KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
title_fullStr KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
title_full_unstemmed KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
title_short KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
title_sort kibra; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968668/
https://www.ncbi.nlm.nih.gov/pubmed/29793439
http://dx.doi.org/10.1186/s12885-018-4491-6
work_keys_str_mv AT mudduwalakmini kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy
AT peirisharshini kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy
AT gunasekarashania kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy
AT abeysiriwardhanadeepthika kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy
AT liyanagenimsha kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy
AT rayalasureshk kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy
AT liyanagethusharie kibraanovelbiomarkerpredictingrecurrencefreesurvivalofbreastcancerpatientsreceivingadjuvanttherapy